He likes it because of it's 16 percent pullback. My thinking is that all big bios have had similar pullbacks. He has been bashing them on his show. Maybe he will change his tune on his show and say buy all of them.
Sentiment: Strong Buy
BIIB got approval on first in class Hemophilia B therapy to reduce bleeding episodes , apparently used once weekly ?? not sure about that but I have 3 family members that would be on this , and cannot imaging the upside potential for anyone with this condition
fairly put activities as well also upper levels indicating long puts however these could have been bought for the Friday sell off, looks like a 90-95 $ move priced in to the upside, anyone know how much this is worth in sales ?
and I can run some valuation's
Stem cell therapy is proving that it is about to change medicine and a small company called Cesca can put Biogen in front of the pack very inexpensively because shares are super cheap and tria results are very powerful.
Cesca therapeutics (KOOL) recently announced record shattering clinical trial results from their 17 patient CLI trial:
Before treatment, 100% of patients required amputation
12 months after treatment, 82.4% of patients had no amputation
Pain level before treatment on a scale of 0 to 10 was severe at 7.8
Pain level 12 months after treatment was almost non-existent at 0.2
6-minute walking distance before treatment was 14.5 meters
6-minute walking distance 12 months after treatment was 157meters
Before treatment, 11 patients had gangrene with or without ulceration
12 months after treatment 0 patients had gangrene or ulceration
NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
THERE WERE NO ADVERSE SIDE EFFECTS.
Biogen or investors can buy Cesca at $20.00 in 12 months when more trial results are announced or they can buy Cesca today at under $2.00.
With trial results such as these, this buyout would establish Biogen as the undisputed leader in Stem Cell Therapy.
Sentiment: Strong Buy
Many are saying the selling is overdone. This is a quote from Ryan Puplava at Financial Sense.
"The correction in momentum and growth areas looks overdone for the time being. I’m seeing volume enter into the area this week at key support levels which indicates weak hands are leaving and strong hands are entering. The NASDAQ Composite is near support and one would expect a short-term bounce here at the very minimum."
boo-right in there with you. been trading this stock along with celg and got caught in this downturn. holding here and hoping for a n ice bounce. still love these stocks for their vast potential. I'm tired of hearing and reading about a biotech bubble. maybe in the smaller names and the host of ipo's but not the big names. top and bottom line growth found here. isn't that what investors want?
this drop as it was industry driven stock sales and nothing to do with the huge potential of this company. NO way do I sell on this computer driven rape of the sector. I stay long. BE THERE. Boolean
Celgene had an approval a couple days ago and it still went down, at some point valuation comes into play ,I think the dust will settle by monday or tuesday
We all know this stock is good at this price. The problem is the 401K customers like the mom and pop. They ignore fundamental and just put in the exchange biotech order to other sector or money market in order to keep profit of last 4 years. It forced the biotech fund managers to sell even with good news !!
Alprolix was approved March 21 in Canada. US approval was just around the corner. Elocate is looking like mid June approval as well as Plegridy. BIIB is a winner all around. It's that rat faced Congressman Waxman who is responsible for this. He's managed to scare 18Billion out of the sector in 7 days! Let's see what Gilead comes back with on April 2nd. Imagine what this will do for innovation in the USA. I guess the future is a burrito.
I want to see more Biotechs get some approvals as well! These are NOT internet stocks of 2000 which had no earnings. These biotechs can only go so low before they recover. One or 2 more approvals in the group and they will be on their way up again I hope!
Too bad they announced this after the close it would have been up for the day instead on down $15.
you got it all wrong, investors are saying its just "OVER VALUED" its in balloon mode, which you can say its in destruction mode.
...Biogen Idec Inc. (NASDAQ: BIIB) was a biotech leader that got crushed recently. Morgan Stanley starts off the stock with an Overweight rating. The company is trading at just 20 times 2015 earnings, and many think that the stock is not overvalued. The consensus price figure for the stock is $345.52. Biogen closed Wednesday at $305.93, down a staggering 15% since the sell-off began.
Today even more drop. This is a bargain here!